Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Despite the successful development of new therapies for the treatment of type 2 diabetes,
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …

Background We assessed the efficacy and safety of the oral glucagon-like peptide-1
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …

Protein and peptide therapeutics require parenteral administration, which can be a deterrent
to medication adherence. For this reason, there have been extensive efforts to develop …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Routes of drug administration and the corresponding physicochemical characteristics of a
given route play significant roles in therapeutic efficacy and short term/long term biological …

The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …

Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-
related glycemic excursions through augmentation of insulin and inhibition of glucagon …

Background Establishing cardiovascular safety of new therapies for type 2 diabetes is
important. Safety data are available for the subcutaneous form of the glucagon-like peptide …